Sana Biotechnology Inc.

AI Score

0

Unlock

3.63
0.17 (4.91%)
At close: Jan 14, 2025, 3:59 PM
3.65
0.41%
Pre-market Jan 15, 2025, 06:26 AM EST
undefined%
Bid 3.6
Market Cap 811.58M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.4
PE Ratio (ttm) -2.6
Forward PE n/a
Analyst Strong Buy
Ask 3.66
Volume 9,351,707
Avg. Volume (20D) 5,398,832
Open 3.43
Previous Close 3.46
Day's Range 3.20 - 3.81
52-Week Range 1.52 - 12.00
Beta undefined

About SANA

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin ...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2021
Employees 328
Stock Exchange NASDAQ
Ticker Symbol SANA

Analyst Forecast

According to 4 analyst ratings, the average rating for SANA stock is "Strong Buy." The 12-month stock price forecast is $13, which is an increase of 257.63% from the latest price.

Buy 75.00%
Hold 25.00%
Sell 0.00%
Stock Forecasts
1 week ago · Source
+160.61%
Sana Biotechnology shares are trading higher after... Unlock content with Pro Subscription
1 week ago · Source
-5.71%
Sana Biotechnology shares are trading higher after the company announced positive clinical trial results from its type 1 diabetes study of islet cell transplantation without immunosuppression.